BRAF and neoplasm: Vemurafenib and, later, dabrafenib, elicited partial responses in most patients with metastatic BRAF-mutant melanoma, and some patients presented complete responses with impressive tumor shrinkage (Flaherty et al., 2010; Hauschild et al., 2012).